title: Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin.
abstract: Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.
authors.affiliation: Department of Urology, Royal Surrey County Hospital, Guildford, UK. Electronic address: Hugh.Mostafid@nhs.net.
authors.forename: A Hugh
authors.initials: AH
authors.lastname: Mostafid
authors.affiliation: Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Palou Redorta
authors.affiliation: Headquarters, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
authors.forename: Richard
authors.initials: R
authors.lastname: Sylvester
authors.affiliation: Department of Urology, Radboud UMC, Nijmegen, The Netherlands.
authors.forename: J Alfred
authors.initials: JA
authors.lastname: Witjes
mesh_terms: D000970:Antineoplastic Agents / Q000600:supply & distribution*; D001500:BCG Vaccine / Q000600:supply & distribution*; D003695:Delivery of Health Care; D006801:Humans; D009361:Neoplasm Invasiveness; D061214:Patient Safety; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine